Agilent plans to spend as much as $270 million to buy an AI pathology company.

Oct 14, 2026, 9:30 AM ETDealRead the original at Benzinga

Good for A

Agilent would add Proscia's pathology software, customer reach and repeat software sales to its lab products. Proscia's sales are small beside its purchase price, but Agilent has cash to fund the deal.

A · Agilent Technologies Inc.

AI read · Good for A

The AI's read

The purchase would pair Proscia's software with Agilent's lab tools, giving customers a more connected way to study tissue samples. Proscia already serves many labs and drug makers, and its repeat software sales could add more profitable offerings. Its sales are small beside the purchase price, but Agilent reported $1.76 billion in cash. The deal still needs closing conditions to be met and is expected to close in fiscal 2027.

Get alerts for A

Follow Agilent Technologies Inc. (A) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for A

Free on the App Store and Google Play, or on the web.